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There are no available pharmacokinetic data to guide piperacillin dosing in critically ill Australian Indigenous patients despite
numerous reported physiological differences. This study aimed to describe the population pharmacokinetics of piperacillin in
critically ill Australian Indigenous patients with severe sepsis. A population pharmacokinetic study of Indigenous patients with
severe sepsis was conducted in a remote hospital intensive care unit. Plasma samples were collected over two dosing intervals
and assayed by validated chromatography. Population pharmacokinetic modeling was conducted using Pmetrics. Nine patients
were recruited, and a two-compartment model adequately described the data. The piperacillin clearance (CL), volume of distri-
bution of the central compartment (Vc), and distribution rate constants from the central to the peripheral compartment and
from the peripheral to the central compartment were 5.6 3.2 liters/h, 14.5 6.6 liters, 1.5 0.4 h1, and 1.8 0.9 h1, respec-
tively, where CL and Vcwere found to be described by creatinine clearance (CLCR) and total body weight, respectively. In this
patient population, piperacillin demonstrated high interindividual pharmacokinetic variability. CLCR was found to be the most
important determinant of piperacillin pharmacokinetics.
Critically ill Australian Indigenous patients have a high mortal-ity rate (1–3). They are reported to be younger and have greater
disease severity and more comorbidity upon admission into the in-
tensive care unit (ICU), of which sepsis and severe sepsis are common
admission diagnoses (1–3). Unfortunately, the lack of evidence-
based antibiotic dosing guidelines in the Indigenous population
makes prescribing a significant challenge for clinicians.
The Australian Indigenous are reported to have various phys-
iological differences compared with non-Indigenous Australians.
For instance, young and healthy Indigenous adults have approxi-
mately 30% fewer nephrons than their non-Indigenous counter-
parts (4). From an anthropometric perspective, they generally
have slightly lower total body weight (TBW), higher central fat,
and slimmer extremities (5). While strong comparative data on
interethnic antibiotic pharmacokinetics generally remain elusive,
a recent systematic review has suggested the possibility of inter-
ethnic differences in antibiotic pharmacokinetics for numerous
antibiotics (6).
Piperacillin is a broad-spectrum antibiotic commonly used in
the critically ill and is considered to have time-dependent bacterial
kill characteristics. Its hydrophilic physicochemistry makes it
prone to pharmacokinetic fluctuations in critically ill patients (7).
To date, there are no data on piperacillin pharmacokinetics in
critically ill Indigenous Australians.
The aim of this study was to describe the population pharma-
cokinetics of piperacillin in critically ill Australian Indigenous
with severe sepsis.
MATERIALS AND METHODS
Setting. An observational population pharmacokinetics study was con-
ducted in a 10-bed ICU at a teaching hospital in remote Central Australia.
Ethics clearance was obtained from the local and university ethics com-
mittees (Central Australian Human Research Ethics Committee, approval
HREC-13-149; The University of Queensland Human Research Ethics
Committee, approval 2013000904).
Study protocol. The dosing regimen for piperacillin, which was coad-
ministered with tazobactam (Tazopip; Aspen Pharmacare, Sydney, Aus-
tralia), was at the discretion of the treating intensivist. Inclusion and ex-
clusion criteria, details of sampling, demographic data collected, and
sample handling were previously published (8).
Drug assay. Piperacillin was measured in plasma (0.5 to 500 mg/liter)
by a validated ultra-high-pressure liquid chromatography–tandem mass
spectrometry spectroscopy (UHPLC-MS/MS) method on a Shimadzu
Nexera2 UHPLC system coupled to a Shimadzu 8030 triple quadrupole
mass spectrometer (Shimadzu, Kyoto, Japan). The methods for this assay
have been described previously (9). The assay method was validated for
linearity, matrix test, selectivity, lower limit of quantification, recovery,
reinjection stability, precision, and accuracy using the Food and Drug
Administration criteria for bioanalysis (10). Precision was within 5.8%
and accuracy was within 10.0% at the tested plasma quality control pip-
eracillin concentrations of 1.5, 50, and 400 mg/liter.
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Population pharmacokinetic modeling. Concentration-time data
obtained from the plasma samples were described by compartment mod-
els using the Pmetrics software package (11) for R (version 3.2.2). Demo-
graphic and clinical data collected were tested for inclusion into the phar-
macokinetic model as covariates. The covariates which statistically
improved the log likelihood (P  0.05) and/or improved the goodness-
of-fit plots were retained in the final model.
Model diagnostics. Model evaluation was performed by visually as-
sessing the goodness of fit of the observed-predicted plots and the coeffi-
cient of determination of the linear regression of the observed-predicted
values (r2 close to 1, intercept close to 0) from each run. The predictive
performance was assessed on mean prediction error (bias) and the mean
biased adjusted squared prediction error (imprecision) of the population
and individual posterior predictions. Visual predictive check plots (VPC)
generated from the final model were also visually assessed to determine
whether the observed data were appropriately distributed within the sim-
ulated model.
Statistical analysis. Continuous data were presented as mean stan-
dard deviation or median interquartile range and categorical data pre-
sented as counts (percent).
RESULTS
Ten Indigenous patients were recruited, and one patient was ex-
cluded due to inappropriate storage of samples. The demograph-
ics and clinical information are presented in Table 1. In total, 139
plasma samples were available for pharmacokinetic analysis.
Population pharmacokinetic model building and model di-
agnostics. A two-compartment model was found to describe the
data adequately. Elimination from the central compartment (rep-
resented by clearance [CL]) and intercompartmental distribution
TABLE 1 Demographic and clinical data
Parametera Value (n 9)b
Age (yr) 43 11
Female (no.) 4 (44)
Wt (kg) 76 11
Height (cm) 170 17
BMI (kg/m2) 27 7
Serum creatinine concn (mol/liter) 95 69
CLCR (ml/min) 91 46
Serum albumin concn (g/liter) 27 5
Vasopressor use (no.) 8 (89)
APACHE II score 23 6
SOFA score 8 2
a BMI, body mass index; CLCR, measured creatinine clearance; APACHE II score, acute
physiological and chronic health evaluation II score; SOFA score, sequential organ
failure assessment score.
b Data are presented as mean standard deviation or as number (percent).
TABLE 2 Pharmacokinetic parameter estimates from two-compartment
modela
Parameter
Total
(n 9)b CV (%) Variance Median
Vc (liters) 14.5 6.6 45.7 44.0 12.2
CL (liters/h) 5.6 3.2 57.0 10.4 4.6
Kcp (h
1) 1.5 0.4 28.2 0.2 1.5
Kpc (h
1) 1.8 0.9 47.5 0.7 1.7
a Vc, volume of distribution in the central compartment; CL, drug clearance; Kcp,
distribution rate constant from central to peripheral compartment; Kpc, distribution
rate constant from peripheral to central compartment; CV, coefficient of variation.
b Data are presented as mean standard deviation.
FIG 1 Diagnostics of final pharmacokinetic model. (A) Plot of population
predicted concentrations versus observed concentrations. (B) Plot of individ-
ual predicted concentrations versus observed concentrations (where the data
presented on both the x and y axes are concentrations in milligrams per liter).
(C) Visual predictive check plot (where output on the y axis is concentration in
milligrams per liter).
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(represented by distribution rate constants from the central to the
peripheral compartment [Kcp] and from the peripheral to the cen-
tral compartment [Kpc]) were modeled as first-order processes
using differential equations. Creatinine clearance (CLCR) and the
patient’s TBW were the only covariates tested which significantly
improved the pharmacokinetic model. The final model was de-
scribed by the equations TVCL CL [(CLCR/55) 0.45] and
TVVc  Vc  (TBW/76)
0.75, where TVCL is the typical value of
piperacillin clearance, CL is the population parameter estimate of
piperacillin clearance, TVVc is the typical value of volume of dis-
tribution of the central compartment,Vc is the population param-
eter estimate of volume of the central compartment, and TBW is
total body weight. The final covariate model had a decrease in2
log likelihood of 33.6 from the base model and improved the
goodness-of-fit plots. The population pharmacokinetic parame-
ter estimates obtained in the two-compartment model are pre-
sented in Table 2.
The goodness of fit for the plots of individual and population
predicted versus observed values and the VPC were considered
acceptable (Fig. 1). The VPC showed an even distribution of the
observed data across the percentiles of the simulated data.
Table 3 compares the pharmacokinetic parameter estimates
observed in our study with other published data from various
patient populations (12–24). The parameter estimates from the
present study generally show a lower mean piperacillin CL than
data on healthy volunteers and critically patients when CLCR was
taken into consideration. On the other hand, Vc values were sim-
ilar across all patient groups.
DISCUSSION
To the best of our knowledge, this is the first study to examine the
population pharmacokinetics of piperacillin in critically ill Aus-
tralian Indigenous patients with severe sepsis. We found that pip-
eracillin pharmacokinetics in this population have high interindi-
vidual variability compared to those in healthy volunteers (12, 13)
but are similar to those in other critically ill or hospitalized pa-
tients (14–24). Nonetheless, we have also found that renal func-
tion, i.e., CLCR, remains the most important determinant of pip-
eracillin dosing requirements.
The mean CL estimate observed in this study was 5.6 liters/h,
which is lower than previously described for healthy volunteers
(12 to 14 liters/h). However, individual estimates in our study
group ranged from 2.8 to 14.2 liters/h, which is not dissimilar to
the range of other published data for critically ill or hospitalized
patients (3 to 40 liters/h) (14–24). Regarding piperacillin volume
of distribution, the Vc in this study was similar to other published
data for both healthy volunteers and critically ill patients (13, 18,
19, 21). These data highlight why there is such high variability in
piperacillin pharmacokinetics, where both supra- and subthera-
peutic concentrations were common.
It is likely that the high interindividual pharmacokinetic differ-
ences observed in this study prevented identification of any inter-
ethnic differences, if such an effect is indeed present. This conclu-
sion is supported by a recent systematic review that suggests that
antibiotics which are eliminated predominantly via glomerular
filtration are less likely to display interethnic pharmacokinetic dif-
ferences (6), in part because the differences can be readily ex-
plained by renal function estimates. Whether the lower mean pip-
eracillin CL observed in our study group, when CLCR was taken in
consideration, is caused by a lower nonrenal clearance requires
further investigation (14–16, 18, 20).
This study has some limitations. First, only plasma piperacillin
concentrations were assessed in this study, which do not reflect
piperacillin concentrations achieved in other tissue sites (25). Sec-
ond, the study was not designed to investigate the unbound pip-
eracillin concentration, and an assumption of 30% albumin bind-
ing was made for our dosing simulations. This is supported by
previous literature (26). Lastly, patients recruited in this study met
the severe sepsis criteria defined by the American College of Chest
Physicians/Society of Critical Care Medicine Consensus Confer-
ence Committee (27), and the study recruitment took place prior
to the publication of the new definition for “sepsis” (28). We ac-
knowledge that the two definitions may result in slightly different
patient groups, and there are few data currently available to define
how different the groups may be.
In conclusion, this study has highlighted that CLCR is the stron-
gest determinant of piperacillin pharmacokinetics in severely sep-
tic Australian Indigenous patients. Therefore, it should be consid-
ered essential to select the dosing regimens for individual patients
according to their measured CLCR.
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